• Explore /
  • Poster
  • / A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Abstract Poster

Authors

Martin Gutierrez

Martin Gutierrez

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;

Martin Gutierrez , Darren Sigal , Kevin Berth , Adam Kuehn , John Colerangle , Sharmila Koppisetti , Shawn He , William van der Touw , Robert Hariri , Mark S. Awadalla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05207722

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS478)

DOI

10.1200/JCO.2023.41.4_suppl.TPS478

Abstract #

TPS478

Poster Bd #

N13

Abstract Disclosures

Similar Posters

First Author: Jin Li

First Author: Haeseong Park

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci